Recommended Duration of Targeted-Release Budesonide in IgA Nephropathy
The recommended duration of targeted-release oral budesonide (Nefecon) for IgA nephropathy is 9 months at 9 mg once daily. 1
Guideline-Based Recommendation
The KDIGO 2025 Clinical Practice Guideline explicitly recommends a 9-month treatment course of targeted-release budesonide (Nefecon) at 9 mg once daily for patients with IgAN who are at risk of progressive loss of kidney function (Recommendation 1.4.3.1, Grade 2B). 1
Important Caveats About This Duration
The guideline acknowledges a critical limitation: a 9-month treatment course may not result in sustained clinical response in terms of proteinuria reduction or eGFR stabilization. 1 The guideline explicitly states that "data on the safety and efficacy of extended or additional treatment courses are awaited," indicating that the optimal duration remains uncertain and 9 months represents the best available evidence rather than a definitively established endpoint. 1
Clinical Context and Practical Considerations
What Happens After 9 Months?
The evidence base does not yet support:
- Extending treatment beyond 9 months
- Repeating courses of therapy
- Maintenance dosing strategies
This represents a significant gap in current knowledge, as many patients may require longer immunosuppression to achieve durable remission. 1
Monitoring During and After Treatment
While on the 9-month course, patients require:
- Antimicrobial prophylaxis against Pneumocystis jirovecii 1
- Antiviral prophylaxis in hepatitis B carriers 1
- Gastroprotection and bone protection per national guidelines 1
- Regular monitoring of eGFR and proteinuria to assess response
Alternative Formulations and Durations
The research evidence shows variable durations with non-targeted budesonide formulations:
- One retrospective study used 24 months of enteric-coated budesonide (Budenofalk): 9 mg/day for 12 months, then 3 mg/day for another 12 months, showing sustained proteinuria reduction 2
- A pediatric case report used 12 months of TRF-budesonide with gradual weaning over the final months 3
However, these are not FDA-approved or guideline-recommended regimens. The targeted-release formulation (Nefecon) differs pharmacologically from enteric-coated budesonide, delivering drug specifically to the ileal Peyer's patches where IgA-producing cells originate. 4
When Targeted-Release Budesonide Is Not Available
If Nefecon is unavailable, KDIGO 2025 recommends systemic glucocorticoids for 6-9 months total duration: 1
- Methylprednisolone 0.4 mg/kg/day (maximum 32 mg/day) for 2 months
- Followed by tapering by 4 mg/day each month
- Total duration: 6-9 months
This regimen carries higher systemic toxicity risk, particularly in patients with eGFR <30 mL/min/1.73 m², diabetes, obesity, or latent infections. 1
Key Clinical Pitfall
Do not assume 9 months is sufficient for all patients. The guideline's acknowledgment that sustained response may not occur highlights the need for close post-treatment monitoring and readiness to consider alternative or additional therapies if disease activity recurs. The field awaits data on retreatment strategies and extended courses. 1